Showing results (221-230 of 572) with videos related to
Sort By:
Pageof 58
Human & Experimental Toxicology|March 25, 2016
The effect of tobacco smoke on oxytocin concentrations and selected oxidative stress parameters in plasma during pregnancy and post-partum - an experimental modelM Napierala, T A Merritt, J Mazela, et al.Frontiers in Neuroscience|May 25, 2017
Decreasing Sedentary Behavior: Effects on Academic Performance, Meta-Cognition, and SleepJune J Pilcher, Drew M Morris, Stewart A Bryant, et al.Journal of Clinical Psychology|November 11, 1992
The Missouri Children's Behavior Checklist behavioral classification system: a construct validity study with nonreferred childrenR J Thompson, K A Merritt, B R Keith, et al.Journal of Veterinary Pharmacology and Therapeutics|August 1, 2007
Absorption, distribution, metabolism, and excretion of dirlotapide in the dogD A Merritt, A J Bessire, A D Vaz, et al.American Journal of Veterinary Research|October 7, 2005
Regional and zonal variations in the sulfation patterns of chondroitin sulfate in normal equine corneal stromaDaniel J Biros, Dennis E Brooks, Murray P Brown, et al.Journal of Interferon Research|June 1, 1986
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administrationJ A Merritt, L A Ball, K M Sielaff, et al.Obstetrics and Gynecology|October 1, 1991
Morbidity associated with prenatal disruption of the dividing membrane in twin gestationsW M Gilbert, S E Davis, C Kaplan, et al.Journal of Veterinary Pharmacology and Therapeutics|May 7, 2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogsM F Yancey, D A Merritt, J A White, et al.Journal of Veterinary Pharmacology and Therapeutics|May 7, 2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumorsM F Yancey, D A Merritt, S P Lesman, et al.Journal of Interferon Research|May 1, 1992
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administrationJ A Merritt, L A Ball, K M Sielaff, et al.Pageof 58